Enanta Pharmaceuticals (ENTA) Free Cash Flow Growth (5y) (2017 - 2026)
Enanta Pharmaceuticals (ENTA) Free Cash Flow Growth (5y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.73% |
| Dec 31, 2025 | 4.95% |
| Sep 30, 2025 | 18.40% |
| Jun 30, 2025 | 41.68% |
| Mar 31, 2025 | -28.36% |
| Dec 31, 2024 | -29.34% |
| Sep 30, 2024 | -47.92% |
| Jun 30, 2024 | -37.08% |
| Mar 31, 2024 | -25.16% |
| Dec 31, 2023 | -23.32% |
| Sep 30, 2023 | -20.07% |
| Jun 30, 2023 | -56.20% |
| Mar 31, 2023 | -13.06% |
| Dec 31, 2022 | -61.91% |
| Sep 30, 2022 | -18.15% |
| Jun 30, 2022 | -40.06% |
| Mar 31, 2022 | -49.24% |
| Dec 31, 2021 | -51.86% |
| Sep 30, 2021 | -72.95% |
| Jun 30, 2021 | -60.68% |